

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

IN THE UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF ILLINOIS  
EASTERN DIVISION

HOSPIRA, INC.,	)	
	)	
Plaintiff,	)	Docket Nos. 16 C 651
	)	17 C 7903
vs.	)	
	)	
FRESENIUS KABI USA, LLC,	)	Chicago, Illinois
	)	July 18, 2018
Defendant.	)	10:10 a.m.

VOLUME 3A  
TRANSCRIPT OF PROCEEDINGS - Bench Trial  
BEFORE THE HONORABLE REBECCA R. PALLMEYER

APPEARANCES:

For the Plaintiff:	JENNER & BLOCK LLP BY: MR. BRADFORD P. LYERLA MR. YUSUF ESAT MR. AARON A. BARLOW MR. REN-HOW H. HARN MS. SARA T. HORTON 353 North Clark Street Chicago, Illinois 60654
For the Defendant:	SCHIFF HARDIN LLP BY: MR. IMRON T. ALY MR. JOEL M. WALLACE MS. TARA L. KURTIS MR. KEVIN M. NELSON 233 South Wacker Drive, Suite 6600 Chicago, Illinois 60606
	SCHIFF HARDIN LLP BY: MR. AHMED M.T. RIAZ 666 Fifth Avenue, 17th Floor New York, New York 10103
Also Present:	Mr. Michael P. Bauer, Hospira Mr. Ryan Daniel, Fresenius Kabi Mr. Ali Ahmed, Fresenius Kabi

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

Court Reporter:

FRANCES WARD, CSR, RPR, RMR, FCRR  
Official Court Reporter  
219 S. Dearborn Street, Suite 2144D  
Chicago, Illinois 60604  
(312) 435-5561  
frances\_ward@ilnd.uscourts.gov

1 THE COURT: All right. We are prepared, I think,  
2 to hear continued cross-examination.

3 MS. HORTON: Yes, your Honor.

4 THE COURT: I want to remind you, sir, that you are  
5 under oath.

6 You may proceed, counsel.

7 JAMES KIPP, DEFENDANT'S WITNESS, PREVIOUSLY SWORN

8 CROSS-EXAMINATION - Resumed

9 BY MS. HORTON:

10 Q. Good morning, Dr. Kipp.

11 A. Good morning.

12 Q. I just have a few more things to ask you about.

13 You mentioned *Remington's* in your testimony  
14 yesterday; is that right?

15 A. Yes.

16 Q. What is *Remington's*?

17 A. It's a general guidance book that formulators would  
18 consult, basically a bible that any formulator would consult.

19 Q. Okay. Let's look at JTX20.1, please.

20 This is *Remington's*?

21 It's also in the binder in front of you, if you  
22 would like to look at the --

23 A. I can see it on the screen.

24 Q. Okay. So yes, this is *Remington's*?

25 A. Yes.

1 Q. Okay. If we could look at Page JTX20.5, please, there  
2 is a heading entitled "Product Stability."

3 Do you see that?

4 A. Yes.

5 Q. And that says, "Many factors affect the stability of a  
6 pharmaceutical product and include the stability of the  
7 active ingredients; the potential interaction between active  
8 and inactive ingredients; the manufacturing process; the  
9 dosage form; the container, liner, closure system; and the  
10 environmental conditions encountered during shipment,  
11 storage, and handling; and the length of time between  
12 manufacture and usage."

13 Is that right?

14 A. Yes.

15 Q. Do you agree with that as a general statement?

16 A. Yes, I do.

17 Q. Okay. Let's talk a little bit more about this, as it  
18 says, container system.

19 We talked yesterday about sealed glass vials.

20 A. Yes.

21 Q. And those have to have stoppers to make sure it's  
22 closed?

23 A. Yes.

24 Q. Okay. And the drug could have some interaction or some  
25 sorption issues with a stopper, right?

1 A. It could, yes.

2 Q. Okay. And one of the ways to deal with that would be to  
3 use a coated stopper?

4 A. Yes.

5 Q. And there are many coated stoppers that you could use on  
6 the market?

7 A. It's not unlimited. There are a few select stoppers  
8 that could be used, yes. They have to be approved and,  
9 obviously, acceptable in pharmaceutical products, especially  
10 in injectables.

11 Q. Are there more than ten on the market?

12 A. I don't know the exact number.

13 Q. Okay. So there is something -- because of this  
14 potential sorption issue, that's why the FDA requires testing  
15 in both the upright and inverted configuration; is that  
16 right?

17 A. Yes.

18 Q. And what's the reason for the inverted testing, I guess?

19 A. Well, you want to look at the worst case. The FDA  
20 always wants you to look at the worst possible case. So the  
21 stopper material would be in constant contact with the fluid  
22 inside the bottle.

23 Q. Okay. And that could be something that happens, for  
24 example, in shipping or handling or something?

25 A. Yes.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.